Skip to main content
Premium Trial:

Request an Annual Quote

Alliance Global Group, Invivoscribe Ink Distribution Deal

NEW YORK (GenomeWeb) – The Alliance Global Group today announced an exclusive master agreement for the distribution of Invivoscribe Technologies' molecular diagnostics in Alliance's markets.

Based in San Diego, Invivoscribe's products include assays for detecting clonal gene rearrangements, gene translocations, and gene mutations in patients with suspected lymphoproliferations, among other things. It also has CLIA- and CAP-certified clinical reference laboratories in the European Union and the US to perform FLT2 and NPM1 mutation testing.

Alliance is headquartered in Dubai, United Arab Emirates and provides biomedical technologies to the Middle East, Africa, and Asia.

Financial and other terms of the deal were not disclosed.